Xoc Pharmaceuticals utilizes state-of-the-art receptor characterization technology and cutting-edge medicinal chemistry to identify product candidates and develop novel therapies to improve safety and efficacy for patients. The Company is focused on the development of novel oral therapies for migraine prevention and dopamine agonism for Parkinson’s disease management. Xoc manages the clinical and regulatory risk in its development programs by leveraging the extensive pharmacological history of compounds similar to product candidates.